Larimar Therapeutics, Inc. (LRMR)
NASDAQ:LRMR
LRMR Stock Chart & Stats
$4.86
-$0.11(-2.78%)
At close: 4:00 PM EST
$4.86
-$0.11(-2.78%)
Day’s Range― - ―
52-Week Range$1.73 - $6.42
Previous CloseN/A
Volume147.46K
Average Volume (3M)2.04M
Market Cap
$503.83M
Enterprise Value$334.56M
Total Cash (Recent Filing)$136.85M
Total Debt (Recent Filing)$4.07M
Price to Earnings (P/E)―
Beta1.75
Next Earnings
May 07, 2026EPS Estimate
-0.55Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.73
Shares Outstanding103,882,935
10 Day Avg. Volume1,345,878
30 Day Avg. Volume2,039,451
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)3.56
Price to Sales (P/S)0.00
P/FCF Ratio-2.45
Enterprise Value/Market Cap0.66
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.28K
Enterprise Value/Ebitda-1.96
Forecast
1Y Price Target
$13.90Price Target Upside186.01% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-1.96
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Biomarker ValidationRegulatory agreement on using skin frataxin as a surrogate endpoint strengthens the filing strategy by providing a measurable marker linked to neurologic benefit.
Clinical Development And Market PotentialTopline open‑label data aimed to support a biologics license application and the prospect of a first disease‑modifying frataxin replacement therapy could generate meaningful commercial interest if confirmatory trials succeed.
Regulatory DesignationFDA Breakthrough Therapy Designation for nomlabofusp and inclusion in a program enabling increased regulator communication support an expedited review pathway and potential eligibility for a priority review voucher.
Bears Say
Comparator And Approval UncertaintyReliance on external natural history data as a comparator requires further regulatory alignment and could complicate approval if regulators view the comparison as insufficient.
Financing RiskLimited cash runway relative to ongoing cash burn creates the need for additional financing, which could dilute investors or disrupt development timelines if not secured.
Safety RiskAnaphylactic reactions observed with nomlabofusp, particularly after treatment interruptions, constitute a serious safety and regulatory concern that could restrict clinical use and affect labeling.
Larimar Therapeutics News
LRMR FAQ
What was Larimar Therapeutics, Inc.’s price range in the past 12 months?
Larimar Therapeutics, Inc. lowest stock price was $1.73 and its highest was $6.42 in the past 12 months.
What is Larimar Therapeutics, Inc.’s market cap?
Larimar Therapeutics, Inc.’s market cap is $503.83M.
When is Larimar Therapeutics, Inc.’s upcoming earnings report date?
Larimar Therapeutics, Inc.’s upcoming earnings report date is May 07, 2026 which is in 23 days.
How were Larimar Therapeutics, Inc.’s earnings last quarter?
Larimar Therapeutics, Inc. released its earnings results on Mar 19, 2026. The company reported -$0.73 earnings per share for the quarter, missing the consensus estimate of -$0.489 by -$0.241.
Is Larimar Therapeutics, Inc. overvalued?
According to Wall Street analysts Larimar Therapeutics, Inc.’s price is currently Undervalued.
Does Larimar Therapeutics, Inc. pay dividends?
Larimar Therapeutics, Inc. does not currently pay dividends.
What is Larimar Therapeutics, Inc.’s EPS estimate?
Larimar Therapeutics, Inc.’s EPS estimate is -0.55.
How many shares outstanding does Larimar Therapeutics, Inc. have?
Larimar Therapeutics, Inc. has 103,882,935 shares outstanding.
What happened to Larimar Therapeutics, Inc.’s price movement after its last earnings report?
Larimar Therapeutics, Inc. reported an EPS of -$0.73 in its last earnings report, missing expectations of -$0.489. Following the earnings report the stock price went up 3.953%.
Which hedge fund is a major shareholder of Larimar Therapeutics, Inc.?
Currently, no hedge funds are holding shares in LRMR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Larimar Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$13.90 (186.01% Upside)
$13.90 (186.01% Upside)
Blogger Sentiment
Bullish
LRMR Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 6.8M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $25.6M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 0.4%
Last 30 Days ▼ 1.4%
Last 30 Days ▼ 1.4%
Technicals
SMA
Positive
20 days / 200 days
Momentum
172.47%
12-Months-Change
Fundamentals
Return on Equity
-137.70%
Trailing 12-Months
Asset Growth
-27.11%
Trailing 12-Months
Company Description
Larimar Therapeutics, Inc.
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.
LRMR Stock 12 Month Forecast
Average Price Target
$13.90
▲(186.01% Upside)
Technical Analysis
Omeros
―
Vanda
―
Foghorn Therapeutics
―
Candel Therapeutics
―
Neumora Therapeutics, Inc.
―
Ownership Overview
Currently, No data available
---